Announced details
The progression of brain metastases was significantly suppressed (specific figures are Not disclosed).
The Company announced research findings from a CNIO research group. The Company plans to advance clinical research with CNIO, Dr. Valiente and others. Capital ties, personnel ties and existing business relationships are Not disclosed.
CNIO is Spain's national cancer research centre. Dr. Valiente heads CNIO's brain metastasis research group. Other information, including its location, representative, capital and year of establishment, is Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Cancer Research (March 2026 issue), paper DOI: 10.1158/0008-5472.CAN-25-4018
| Item | Details |
|---|---|
| Names of Products / Services Covered | MN-166 (ibudilast) |
| Counterparty | Spanish National Cancer Research Centre (CNIO), Dr. Manuel Valiente |
| Counterparty overview | CNIO is Spain's national cancer research centre. Dr. Valiente heads CNIO's brain metastasis research group. Other information, including its location, representative, capital and year of establishment, is Not disclosed. |
| Relationship with the Company | The Company announced research findings from a CNIO research group. The Company plans to advance clinical research with CNIO, Dr. Valiente and others. Capital ties, personnel ties and existing business relationships are Not disclosed. |
| Applicable area | Brain metastases from solid tumors, Neuro-oncology |
| Quantitative Effects | The progression of brain metastases was significantly suppressed (specific figures are Not disclosed). |
| Source | Cancer Research (March 2026 issue), paper DOI: 10.1158/0008-5472.CAN-25-4018 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The research indicated that the progression of brain metastases may be suppressed by inhibiting MIF–CD74 signaling and identified potential biomarkers for predicting treatment response.